Filtered By:
Source: Europace

This page shows you your search results in order of date. This is page number 10.

Order by Relevance | Date

Total 183 results found since Jan 2013.

Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation
The current manuscript is an update of the original Practical Guide, published in June 2013[Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625–51; Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013;34:2094–106]. Non-vitamin K antagonist oral anticoagulants (NOACs) are an ...
Source: Europace - October 23, 2015 Category: Cardiology Authors: Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H.-C., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., Kirchhof, P., Advisors:, Ahmad, Heinrich-Nols, Hess, Muller, Munzel, Schwertfeger, Van Eickels, Richard-Lordereau, Document reviewers:, L Tags: EHRA PRACTICAL GUIDE Source Type: research

Combined catheter ablation and left atrial appendage closure as a hybrid procedure for the treatment of atrial fibrillation
Conclusions The combination of CA and percutaneous LAAC in a single procedure is technically feasible in patients with symptomatic drug-refractory AF, high risk of stroke, and contraindications to OACs, although it is associated with a significant risk of major complications.
Source: Europace - October 23, 2015 Category: Cardiology Authors: Calvo, N., Salterain, N., Arguedas, H., Macias, A., Esteban, A., Garcia de Yebenes, M., Gavira, J. J., Barba, J., Garcia-Bolao, I. Tags: Ablation for atrial fibrillation Source Type: research

Left atrial catheter ablation subsequent to Watchman(R) left atrial appendage device implantation: a single centre experience
Conclusion Left atrial catheter ablation therapy in the presence of an implanted Watchman® left atrial appendage occlusion device was efficacious and uncomplicated in our small single centre experience.
Source: Europace - October 6, 2015 Category: Cardiology Authors: Walker, D. T., Phillips, K. P. Tags: Ablation for atrial fibrillation Source Type: research

Relationship between Mediterranean diet and time in therapeutic range in atrial fibrillation patients taking vitamin K antagonists
Conclusion In our cohort of AF patients, Med-Diet is not associated with changes in TTR, and thus can be recommended for AF patients who are taking VKAs.
Source: Europace - August 13, 2015 Category: Cardiology Authors: Pignatelli, P., Pastori, D., Vicario, T., Bucci, T., Del Ben, M., Russo, R., Tanzilli, A., Nardoni, M. L., Bartimoccia, S., Nocella, C., Ferro, D., Saliola, M., Cangemi, R., Lip, G. Y. H., Violi, F. Tags: Atrial fibrillation Source Type: research

Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation
Stroke is a leading cause of morbidity and mortality worldwide. Atrial fibrillation (AF) is an independent risk factor for stroke, increasing the risk five-fold. Strokes in patients with AF are more likely than other embolic strokes to be fatal or cause severe disability and are associated with higher healthcare costs, but they are also preventable. Current guidelines recommend that all patients with AF who are at risk of stroke should receive anticoagulation. However, despite this guidance, registry data indicate that anticoagulation is still widely underused. With a focus on the 2012 update of the European Society of Car...
Source: Europace - June 26, 2015 Category: Cardiology Authors: Camm, A. J., Pinto, F. J., Hankey, G. J., Andreotti, F., Hobbs, F. D. R., on behalf of the Writing Committee of the Action for Stroke Prevention alliance, on behalf of the Writing Committee of the Action for Stroke Prevention alliance, John Camm, Pinto, H Tags: REVIEW Source Type: research

Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent ECG recording
Conclusions With the use of a decision analytic simulation model, it has been shown that screening for asymptomatic AF in 75/76-year-old individuals is cost-effective.
Source: Europace - June 26, 2015 Category: Cardiology Authors: Aronsson, M., Svennberg, E., Rosenqvist, M., Engdahl, J., Al-Khalili, F., Friberg, L., Frykman-Kull, V., Levin, L.-A. Tags: Atrial fibrillation Source Type: research

Clinical outcome as a function of the PR-interval--there is virtue in moderation: data from the Duke Databank for cardiovascular disease
Conclusion In patients with coronary heart disease, a prolongation of the PR-interval was not independently associated with poor outcomes, but a PR-interval shorter than normal was associated with increased all-cause mortality and other major cardiovascular events.
Source: Europace - May 28, 2015 Category: Cardiology Authors: Holmqvist, F., Thomas, K. L., Broderick, S., Ersboll, M., Singh, D., Chiswell, K., Shaw, L. K., Hegland, D. D., Velazquez, E. J., Daubert, J. P. Tags: Electrocardiology and risk stratification Source Type: research

Oral anticoagulant therapy for stroke prevention in patients with atrial fibrillation undergoing ablation: results from the First European Snapshot Survey on Procedural Routines for Atrial Fibrillation Ablation (ESS-PRAFA)
We present the results pertinent to the use of antithrombotic therapies. Thirteen countries prospectively enrolled 455 eligible consecutive patients [mean age 59 ± 10.8 years, 131 (28.8%) females]. The mean CHA2DS2-VASc score was 1.12 ± 1.06 [137 patients (30.1%) had a score of ≥2]. Before ablation, 443 patients (97.4%) were on anticoagulant therapy [143 (31.4%) on non-vitamin K antagonist oral anticoagulants (NOACs) and 264 (58.0%) on vitamin K antagonists (VKAs)]. Of the latter, 79.7% underwent ablation without VKA interruption, whilst a variety of strategies were used in patients taking NOAC. After abla...
Source: Europace - May 28, 2015 Category: Cardiology Authors: Potpara, T. S., Larsen, T. B., Deharo, J. C., Rossvoll, O., Dagres, N., Todd, D., Pison, L., Proclemer, A., Purefellner, H., Blomstrom-Lundqvist, C., Conducted by the Scientific Initiatives Committee of the European Heart Rhythm Association (EHRA), Conduc Tags: EHRA SURVEY Source Type: research

Preference for oral anticoagulation therapy for patients with atrial fibrillation in Europe in different clinical situations: results of the European Heart Rhythm Association Survey
The purpose of this European Heart Rhythm Association Survey was to assess the clinical practice in relation to the use of oral anticoagulation therapy for patients with atrial fibrillation (AF) in Europe. Of special interest were patients undergoing percutaneous coronary intervention (PCI), cardioversion procedures, catheter ablation, surgery, and those suffering from anticoagulation-related bleeding. Of 38 responding centres, non-vitamin K antagonist oral anticoagulants (NOACs) were used for stroke prophylaxis and were preferred (33.3%) or considered equal (48.5%) to vitamin K antagonists (VKAs). Only 3% did not use NOAC...
Source: Europace - April 29, 2015 Category: Cardiology Authors: Larsen, T. B., Potpara, T., Dagres, N., Proclemer, A., Sciarrafia, E., Blomstrom-Lundqvist, C., Scientific Initiative Committee, European Heart Rhythm Association, Scientific Initiative Committee, European Heart Rhythm Association, Blomstrom-Lundqvist, Bo Tags: EP WIRE Source Type: research

Optimizing stroke prevention in atrial fibrillation: better adherence and compliance from patients and physicians leads to better outcomes
Source: Europace - April 1, 2015 Category: Cardiology Authors: Potpara, T. S., Lane, D. A., Lip, G. Y. H. Tags: EDITORIALS Source Type: research

Drug persistence with rivaroxaban therapy in atrial fibrillation patients--results from the Dresden non-interventional oral anticoagulation registry
Conclusion Our data indicate that overall persistence with rivaroxaban therapy is high, with a discontinuation rate of ~15% in the first year of treatment and few additional discontinuations thereafter.
Source: Europace - April 1, 2015 Category: Cardiology Authors: Beyer-Westendorf, J., Forster, K., Ebertz, F., Gelbricht, V., Schreier, T., Gobelt, M., Michalski, F., Endig, H., Sahin, K., Tittl, L., Weiss, N. Tags: Atrial fibrillation Source Type: research

Left atrial appendage closure-indications, techniques, and outcomes: results of the European Heart Rhythm Association Survey
In conclusion, this EP Wire has demonstrated that LAAO is most commonly employed in patients at high thrombo-embolic risk in whom OAC is contraindicated. The technique is not yet very widespread and the complication rates remain significant.
Source: Europace - April 1, 2015 Category: Cardiology Authors: Pison, L., Potpara, T. S., Chen, J., Larsen, T. B., Bongiorni, M. G., Blomstrom-Lundqvist, C., Conducted by the Scientific Initiative Committee, European Heart Rhythm Association, Conducted by the Scientific Initiative Committee, European Heart Rhythm Ass Tags: EP WIRE Source Type: research

Silent ischaemic brain lesions related to atrial high rate episodes in patients with cardiac implantable electronic devices
Conclusion Cardiac implantable electronic devices can accurately detect AF as AHRE. Atrial high rate episodes were associated to a higher incidence of silent IBL on CT scan. Atrial high rate episodes represent a kind of silent AF where management recommendations are lacking despite the fact that a higher embolic risk is present.
Source: Europace - February 26, 2015 Category: Cardiology Authors: Benezet-Mazuecos, J., Rubio, J. M., Cortes, M., Iglesias, J. A., Calle, S., de la Vieja, J. J., Quinones, M. A., Sanchez-Borque, P., de la Cruz, E., Espejo, A., Farre, J. Tags: Atrial fibrillation Source Type: research

Long-term clinical outcome of patients who failed catheter ablation of atrial fibrillation
Conclusion More than 5 years after a failed AF ablation, a small minority of patients had such an impaired quality of life as to require non-pharmacological interventions. Almost half developed permanent AF, which significantly impaired quality of life. Permanent AF was more common in patients who had left atrial enlargement, history of persistent AF, longer follow-up, and had performed a single ablation procedure, thus hypothesizing that reablation could reduce the chronicization of arrhythmia. A low risk of stroke was observed in the long-term follow-up.
Source: Europace - February 26, 2015 Category: Cardiology Authors: Bottoni, N., Bertaglia, E., Donateo, P., Quartieri, F., Iori, M., Maggi, R., Zoppo, F., Brandolino, G., Brignole, M. Tags: Ablation for atrial fibrillation Source Type: research

How are patients with atrial fibrillation approached and informed about their risk profile and available therapies in Europe? Results of the European Heart Rhythm Association Survey
This European Heart Rhythm (EHRA) Scientific Initiatives Committee EP Wire Survey aimed at exploring the common practices in approaching patients with atrial fibrillation (AF) and informing them about their risk profiles and available therapies in Europe. In the majority of 53 responding centres, patients were seen by cardiologists (86.8%) or arrhythmologists (64.2%). First- and follow-up visits most commonly lasted 21–30 and 11–20 min (41.5 and 69.8% of centres, respectively). In most centres (80.2%) stroke and bleeding risk had the highest priority for discussion with AF patients; 50.9% of centres had a struc...
Source: Europace - February 26, 2015 Category: Cardiology Authors: Potpara, T. S., Pison, L., Larsen, T. B., Estner, H., Madrid, A., Blomstrom-Lundqvist, C., Conducted by the Scientific Initiatives Committee, and European Heart Rhythm Association, Conducted by the Scientific Initiatives Committee, and European Heart Rhyt Tags: EP WIRE Source Type: research